![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: FLG2 |
Gene summary for FLG2 |
![]() |
Gene information | Species | Human | Gene symbol | FLG2 | Gene ID | 388698 |
Gene name | filaggrin family member 2 | |
Gene Alias | IFPS | |
Cytomap | 1q21.3 | |
Gene Type | protein-coding | GO ID | GO:0002009 | UniProtAcc | Q5D862 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
388698 | FLG2 | HCC1 | Human | Liver | HCC | 1.73e-10 | 1.15e+00 | 0.5336 |
388698 | FLG2 | HCC2 | Human | Liver | HCC | 3.58e-20 | 1.18e+00 | 0.5341 |
388698 | FLG2 | HCC5 | Human | Liver | HCC | 3.79e-21 | 1.18e+00 | 0.4932 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Liver | Cyst | ![]() |
Lung | IAC | ![]() |
Lung | AIS | ![]() |
Lung | AAH | ![]() |
Lung | MIAC | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:005087822 | Liver | HCC | regulation of body fluid levels | 191/7958 | 379/18723 | 1.06e-03 | 6.11e-03 | 191 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
FLG2 | SNV | Missense_Mutation | c.4661N>T | p.Ser1554Phe | p.S1554F | Q5D862 | protein_coding | tolerated(0.21) | benign(0.135) | TCGA-A2-A04V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | PD | |
FLG2 | SNV | Missense_Mutation | c.2326G>T | p.Gly776Cys | p.G776C | Q5D862 | protein_coding | deleterious(0.02) | probably_damaging(0.94) | TCGA-A7-A26G-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | SD | |
FLG2 | SNV | Missense_Mutation | novel | c.570N>C | p.Trp190Cys | p.W190C | Q5D862 | protein_coding | tolerated(0.06) | probably_damaging(0.962) | TCGA-A7-A4SE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | CR |
FLG2 | SNV | Missense_Mutation | c.6917G>C | p.Arg2306Thr | p.R2306T | Q5D862 | protein_coding | tolerated(0.14) | possibly_damaging(0.879) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
FLG2 | SNV | Missense_Mutation | rs769383959 | c.4567G>A | p.Gly1523Ser | p.G1523S | Q5D862 | protein_coding | tolerated(0.1) | benign(0.178) | TCGA-AC-A3W7-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | femara | SD |
FLG2 | SNV | Missense_Mutation | c.1763G>A | p.Gly588Asp | p.G588D | Q5D862 | protein_coding | tolerated(0.15) | benign(0.348) | TCGA-AN-A0FK-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
FLG2 | SNV | Missense_Mutation | c.3868N>A | p.Glu1290Lys | p.E1290K | Q5D862 | protein_coding | tolerated(0.55) | benign(0.045) | TCGA-BH-A0BP-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
FLG2 | SNV | Missense_Mutation | c.1448G>T | p.Gly483Val | p.G483V | Q5D862 | protein_coding | tolerated(0.15) | probably_damaging(0.938) | TCGA-BH-A0BZ-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | CR | |
FLG2 | SNV | Missense_Mutation | c.4922G>C | p.Arg1641Thr | p.R1641T | Q5D862 | protein_coding | tolerated(0.6) | benign(0) | TCGA-BH-A0HK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | |
FLG2 | SNV | Missense_Mutation | c.890N>T | p.Ser297Phe | p.S297F | Q5D862 | protein_coding | tolerated(0.08) | benign(0.135) | TCGA-BH-A1EY-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |